Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia

Abstract To assess the effect of alfuzosin (XATRAL) 10 mg once daily on sexual function in men with moderate to severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), patients with suggestive symptomatic BPH, an International Prostate Symptom Score (IPSS) >...

Full description

Saved in:
Bibliographic Details
Published in:The Kaohsiung journal of medical sciences 2012-08, Vol.28 (8), p.429-434
Main Authors: Hwang, Thomas I.S, Chu, Sheng-Hsien, Lin, Mao-Sheng, Chen, Chih-Shou, Lee, Liang-Ming, Chang, Hong-Chiang, Yeh, Shauh-Der, Chen, Wen-Hsiang, Chiang, Po-Hui
Format: Article
Language:English
Subjects:
Aged
Alfuzosin
Benign prostatic hyperplasia
Drug Administration Schedule
Erectile Dysfunction - drug therapy
Erectile Dysfunction - physiopathology
Humans
Impotence
Internal Medicine
Lower urinary tract symptoms
Lower Urinary Tract Symptoms - drug therapy
Lower Urinary Tract Symptoms - physiopathology
Male
Middle Aged
Patient compliance
Prostatic Hyperplasia - drug therapy
Prostatic Hyperplasia - physiopathology
Quinazolines - administration & dosage
Quinazolines - therapeutic use
Sex (Psychology)
Sexual dysfunction
Sexual Dysfunction, Physiological - drug therapy
Sexual Dysfunction, Physiological - physiopathology
Taiwan
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract To assess the effect of alfuzosin (XATRAL) 10 mg once daily on sexual function in men with moderate to severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), patients with suggestive symptomatic BPH, an International Prostate Symptom Score (IPSS) >8 (range of scores, 0–35), and sexual attempts at least once per month were enrolled. All patients received alfuzosin 10 mg once daily for 24 weeks and were asked to complete the IPSS test and Male Sexual Health Questionnaire at weeks 0 (baseline), 1, 4, 12, and 24. Other assessments included the International Index of Erectile Function—five-item version (range of scores: 5–25), as well as onset of action and peak urinary flow rate ( Qmax ). From September 2006 to May 2008, 279 patients were enrolled from nine centers in Taiwan. At 24 weeks, alfuzosin effectively improved LUTS and quality of life, as demonstrated by a reduction in the IPSS total score (17.3 vs. 9.9, p  
ISSN:1607-551X
2410-8650
DOI:10.1016/j.kjms.2012.02.013